The insider sales are routine and likely tax-related from vesting grants. The real catalyst is the company's pivot to cardiovascular with EDG-7500 Phase 3 starting Q4 2026 and a $2.01B cash position. Monitor for Phase 3 enrollment updates and any further insider selling that deviates from this pattern.
Price Chart
Executive Summary
Five C-suite insiders at Edgewise Therapeutics sold a total of ~$401K in open-market shares on August 12, 2026, following the company's Q2 earnings miss and the transformative sevasemten sale to Servier. The sales are small relative to the $4.8B market cap (0.008%), but the cluster of all top executives selling on the same day after a major corporate pivot warrants attention. The non-cash grants and derivative exercises on the same date suggest these sales are likely liquidity-driven to cover tax obligations from vesting, not a bearish signal on the company's cardiovascular-focused future.
Key Financial Metrics
Key Facts
- Five C-suite insiders (CEO, CFO, CMO, CSO, CBO) sold shares on August 12, 2026
- Total open-market sales: ~$401K, or 0.008% of $4.8B market cap
- Sales occurred 6 days after Q2 2026 earnings miss ($0.53 loss vs $0.47 consensus) and the $1.55B sevasemten sale to Servier
- All insiders also received large non-cash stock grants and exercised derivatives on the same date, indicating tax-withholding sales
- The cluster is small in dollar terms and likely driven by vesting schedules, not a coordinated bearish view
Financial Impact
Total insider sales of ~$401K, immaterial relative to $4.8B market cap
Risk Factors
- Insider sales could accelerate if stock rallies on pipeline news
- Pre-revenue company with widening operating losses; cash burn may accelerate as Phase 3 begins
- Any delay in Phase 3 start or negative data would be highly bearish
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-EWTX-1787007679886 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Insider Cluster | $44.17 $44.62 | ▲ +1.02% | ▲ +3.01% | $41.22 (−6.68%) |
Aug 14, 2026 7w ago | Insider Cluster | $44.17 $44.62 | ▲ +1.02% | ▲ +3.01% | $41.22 (−6.68%) |
Aug 6, 2026 8w ago | 8-K | $44.42 $41.95 | ▼ −5.56% | ▼ −6.16% | $41.22 (−7.20%) |
Jul 13, 2026 11w ago | 8-K | $41.27 $44.58 | ▲ +8.02% | ▲ +4.84% | $41.22 (−0.12%) |
Jun 1, 2026 17w ago | 8-K | $40.26 $40.63 | ▲ +0.92% | ▲ +2.22% | $41.22 (+2.38%) |
May 7, 2026 21w ago | 8-K | $35.58 $36.21 | ▲ +1.77% | ▼ −1.37% | $41.22 (+15.85%) |
Apr 23, 2026 23w ago | DEFA14A | $31.58 $32.69 | ▲ +3.51% | ▼ −0.51% | $41.22 (+30.53%) |
Mar 27, 2026 26w ago | 144 | $30.28 $30.99 | ▲ +2.34% | ▼ −10.25% | $41.22 (+36.13%) |
Feb 26, 2026 31w ago | 8-K | $29.66 $31.65 | ▲ +6.71% | ▲ +13.11% | $41.22 (+38.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access